Navigation Links
Baxter Recalls Rest of Heparin Products
Date:2/28/2008

Investigation into allergic reactions, deaths related to blood thinner continues

THURSDAY, Feb. 28 (HealthDay News) -- Baxter Healthcare Corp., the pharmaceutical company at the center of recent problems with its blood thinner heparin, announced Thursday that it was recalling any remaining multi-dose vials of the drug as well as single-dose vials.

The company also said it was recalling its Hep-Lock heparin flush products, which contain a small amount of heparin and are used to prevent blood clots in intravenous lines.

The recalls were made possible because the other manufacturer of multi-dose heparin vials -- APP Pharmaceuticals of Schaumburg, Ill. -- was able to assure the U.S. Food and Drug Administration that it could meet the demand for the blood thinner in the United States.

"At the time [in January] when Baxter stopped production of its multi-dose heparin, we determined there would be an immediate and severe shortage of this medically necessary drug," Rear Admiral Dr. Sandra Kweder, deputy director of FDA's Office of New Drugs in the Center for Drug Evaluation and Research, said during an afternoon teleconference Thursday. "Therefore, it was in the interest of the public health to allow multi-dose vials to remain on the market, but to be used with caution."

"Today," Kweder added, "we can report that APP is now able to adequately supply the U.S. market."

As far as Baxter's Hep-Lock products are concerned, there are several manufacturers of similar items, Kweder added.

"We have assurance from the U.S. Food and Drug Administration that there is an adequate supply in the market to meet the demand for these critical and lifesaving drugs," Peter J. Arduini, president of Baxter's Medication Delivery business, said in a statement. "The safety and quality of our products is always our highest priority, and we will continue to collaborate with the FDA as we work to determine the cause of t
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Baxter International Third Quarter 2007 Financial Results Conference Call
2. Baxter Reports Strong Third Quarter Sales and Earnings
3. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
4. Fairbank Farms Voluntarily Recalls 85% Ground Round Beef Patties Sold Fresh from Shaws Due to Possible Health Risk
5. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
6. Manufacturer Halts Production of Blood Thinner Heparin
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
9. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
10. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
11. Why Are Most Health & Wellness Products Doomed to Failure?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Baxter Recalls Rest of Heparin Products 
Baxter Recalls Rest of Heparin Products
Breaking Medicine Technology:New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Confusion Over Homeopathic Medicines in Alexa Ray Joel's Hospitalization Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 1DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 3DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 4DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 5DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 6Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 1Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 2Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 1YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 2YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 4